פיקריי 200 מ"ג - Piqray 200 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors | ||||||||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||||||||||||||||||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||||||||
| ×ת×××× | PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CAmutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen | ||||||||||||||||||||||||
| |||||||||||||||||||||||||
| ×ת××××ת × ×× | Contraindications | ||||||||||||||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | ||||||||||||||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | ||||||||||||||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | ||||||||||||||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | ||||||||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| פ×קר×× 200 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | NOVARTIS PHARMA STEIN AG, SWITZERLAND |
| ×©× ××¢× ×ר×ש×× | NOVARTIS ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 6/2019. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 19/06/2025 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־20 ביוני 2025 ב־06:32